home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

95.31 -2.32 (-2.38%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

27 28 Next >

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2024

From Incyte

Via Business Wire

Assessing Incyte: Insights From 11 Financial Analysts ↗

October 01, 2024

Via Benzinga

Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate ↗

September 30, 2024

Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC...

Via Benzinga

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

September 25, 2024

From Incyte

Via Business Wire

Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) ↗

September 03, 2024

Via Benzinga

Analyst Expectations For Incyte's Future ↗

August 15, 2024

Via Benzinga

Analyst Ratings For Incyte ↗

July 26, 2024

Via Benzinga

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets ↗

September 18, 2024

Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist...

Via Benzinga

Topics Intellectual Property

Wall Street Lower Ahead Of Interest Rate Move ↗

September 18, 2024

Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today.

Via Talk Markets

Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers ↗

September 16, 2024

Intel kept running late on yet another big deal.

Via Investor's Business Daily

Topics Stocks

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

September 14, 2024

From Incyte

Via Business Wire

Looking for growth without the hefty price tag? Consider NASDAQ:INCY. ↗

July 22, 2024

INCYTE CORP (NASDAQ:INCY) is showing decent growth, but is still valued reasonably.

Via Chartmill

Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium

September 14, 2024

From Incyte

Via Business Wire

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 09, 2024

From Incyte

Via Business Wire

Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024

August 21, 2024

From Incyte

Via Business Wire

Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study ↗

August 16, 2024

Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in relapsed follicular lymphoma patients, showing positive progression-free...

Via Benzinga

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

August 15, 2024

From Incyte

Via Business Wire

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication ↗

August 15, 2024

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious...

Via Benzinga

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

August 14, 2024

From Incyte and Syndax Pharmaceuticals

Via Business Wire

Incyte to Present at Upcoming Investor Conferences

August 13, 2024

From Incyte

Via Business Wire

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 07, 2024

From Incyte

Via Business Wire

After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial ↗

July 31, 2024

MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference.

Via Benzinga

Topics Death

Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance ↗

July 30, 2024

Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi...

Via Benzinga

Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

July 30, 2024

From Incyte

Via Business Wire

NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

July 10, 2024

INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals.

Via Chartmill

S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday? ↗

July 09, 2024

The S&P 500 index climbed to new all-time highs, rising 0.3% during Tuesday’s session, aiming for a potential sixth consecutive positive close and remaining resilient after Fed Chair Jerome Powell‘s...

Via Benzinga

Topics Economy Stocks

Incyte to Report Second Quarter Financial Results

July 09, 2024

From Incyte

Via Business Wire

The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024 ↗

July 09, 2024

The stock market watches this investing guru's picks closely but these may be the best undervalued Cathie Wood stocks in her ETFs.

Via InvestorPlace

7 Cheap Biotech Stocks With Major Upside Potential ↗

July 09, 2024

While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.

Via InvestorPlace

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 08, 2024

From Incyte

Via Business Wire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

27 28 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com